4D Molecular Therapeutics, Inc. Number of Operating Segments
4D Molecular Therapeutics, Inc. (FDMT) reported Number of Operating Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. number of operating segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. number of operating segments for the quarter ending 2025-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. number of operating segments for the quarter ending 2024-03-31 was 1.00 Segment.
- 4D Molecular Therapeutics, Inc. number of operating segments for the quarter ending 2022-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. number of operating segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- 4D Molecular Therapeutics, Inc. number of operating segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- 4D Molecular Therapeutics, Inc. number of operating segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- 4D Molecular Therapeutics, Inc. number of operating segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-18 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-28 | |||
| 2024-09-30 | 1.00 Segment 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 1.00 Segment 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 1.00 Segment 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-02-29 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-15 | |||
| 2022-09-30 | 1.00 Segment 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 1.00 Segment 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.00 Segment 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-28 | |||
| 2021-09-30 | 1.00 Segment 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 1.00 Segment 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 1.00 Segment 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |